Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**sodium phosphate dibasic heptahydrate + sodium phosphate monobasic** is a parenteral phosphate replacement product used to prevent or correct hypophosphatemia, particularly in patients with restricted or absent oral intake. It is marketed as **Sodium Phosphates Injection, USP, 3 mM P/mL** and contains sodium phosphate salts that provide elemental phosphorus for addition to large-volume intravenous fluids or compounded parenteral nutrition formulations. Mechanistically, it acts as an **electrolyte and phosphate replenisher**, restoring systemic phosphate needed for intracellular energy metabolism, including ATP generation, red blood cell glucose utilization, and other phosphorylation-dependent biological processes. The product is manufactured as a generic hospital injectable by companies including Pfizer, Fresenius Kabi, and Civica.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium phosphate dibasic heptahydrate + sodium phosphate monobasic.